Showing results (491-500 of 1,946) with videos related to

Sort By:
Pageof 195
RMD Open|August 19, 2026
Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic reviewJames Kimpton, Akpabio Akpabio, Andrew Watts, et al.
RMD Open|August 20, 2026
Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management-a multicentre, randomised, open-label trialAgnes E M Looijen, Hamit Harun Dag, Judith W Heutz, et al.
RMD Open|November 25, 2021
Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseasesFilipa Oliveira Ramos, Ana Rodrigues, Fernando Magalhaes Martins, et al.
RMD Open|November 25, 2021
Validation of a machine learning approach to estimate Clinical Disease Activity Index Scores for rheumatoid arthritisAlison K Spencer, Jigar Bandaria, Michelle B Leavy, et al.
RMD Open|November 25, 2021
Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC studyMarlou Thf Janssen, Sofia Ramiro, Rémy Lm Mostard, et al.
RMD Open|December 4, 2021
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximabCathy Mireille Melong Pianta Taleng, Kim Lauper, Benoit Gilbert, et al.
RMD Open|March 20, 2019
Undifferentiated connective tissue disease: state of the art on clinical practice guidelinesMargarida Antunes, Carlo Alberto Scirè, Rosaria Talarico, et al.
RMD Open|March 20, 2019
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analysesErnest Choy, Nick Freemantle, Clare Proudfoot, et al.
RMD Open|March 20, 2019
Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
Pageof 195